Rigshospitalet

Endothel Pharma Aps

Pär Ingemar Johansson

Sisse Rye Ostrowski

Philip E Hansen

Jens Kindtler

Louise Bochsen

Niels H Secher

Use of prostacyclin or an analogue thereof for treatment of a new medical indication in acute critically ill patients, in particular acute critically ill patients with systemic endothelial damage, a biomarker for identifying individuals that have a new medical indication, and a method for identifying a new medical indication.

Composition comprising prostacyclin andor analogues thereof for treatment of acute critically ill patients

The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability.

Injectable pharmaceutical compositions comprising adrenaline and citric acid

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength

Growing community of inventors

Dösjebro, Sweden

Pär Ingemar Johansson